Putting Patients First Blog

JUNE 26, 2025

The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. Even well-intentioned policies can create access disparities if communication and operational support are lacking.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Putting Patients First Blog

SEPTEMBER 3, 2024

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling Communication 52

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Valuing life differently based on disability status, age, or other special populations is inappropriate.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

APRIL 14, 2023

10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. The NHC believes that CMS may need to reevaluate methodology for various pieces of the negotiation process, including aggregating drugs to determine MFP.

Drug Pricing 40

Drug Pricing Drug Development Documentation Communication 40

Putting Patients First Blog

SEPTEMBER 20, 2024

NHC Provides Input on Patient Engagement in Medicare Drug Price Negotiations September 20, 2024 By: Allen Pinn, Coordinator, Policy August 16 marked two years since the Inflation Reduction Act (IRA) was signed into law. Earlier this year CMS released draft guidance for Initial Payment Applicability Year (IPAY) 2027.

Drug Pricing 52

Drug Pricing Communication Vaccines 52

Pharmaceutical Technology

JULY 1, 2025

The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. How will RFK Jr’s American dream for vaccines play out? Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Communication 52

Communication Packaging Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 2, 2025

The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52